When the placebo isn’t inert: Rezolute’s CEO on the 40% response rate that upended a phase 3 trial

As recently as December 10, 2025, Rezolute was a Wall Street darling. Eight analysts rated the stock a Buy, with price targets as high as $17. Its lead drug ersodetug, a monoclonal antibody, had earned two FDA Breakthrough Therapy Designations and the agency had signaled that its Phase 3 trial could support a BLA filing.… The post When the placebo isn’t inert: Rezolute’s CEO on the 40% response rate that upended a phase 3 trial appeared first on Drug Discovery and Development.

Continue reading →